Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:02:24 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:MORF from 2023-04-20 to 2024-04-19 - 23 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-19 08:00U:MORFNews ReleaseMorphic Appoints Dr. Simon Cooper as Chief Medical Officer
2024-03-05 16:05U:MORFNews ReleaseMorphic to Participate in March Investor Conferences
2024-02-22 07:00U:MORFNews ReleaseMorphic Announces Corporate Highlights and Financial Results for the Full Year 2023
2024-01-03 16:05U:MORFNews ReleaseMorphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-11 05:31U:MORFNews ReleaseINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
2023-12-04 05:02U:MORFNews ReleaseSHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Morphic Holding, Inc. and Encourages Investors with Losses to Contact the Firm
2023-11-10 08:00U:MORFNews ReleaseMorphic to Present at November Investor Conferences
2023-11-03 07:00U:MORFNews ReleaseMorphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
2023-10-09 08:00U:MORFNews ReleaseMorphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
2023-09-26 16:10U:MORFNews ReleaseMorphic Holdings Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave of Absence
2023-09-22 17:30U:MORFNews ReleaseMorphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
2023-08-29 08:00U:MORFNews ReleaseMorphic Announces Participation in 2023 Wells Fargo Healthcare Conference
2023-08-09 16:05U:MORFNews ReleaseMorphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
2023-08-03 07:05U:MORFNews ReleaseMorphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023
2023-06-06 16:05U:MORFNews ReleaseMorphic to Present at the Jefferies Global Healthcare Conference
2023-05-12 08:30U:MORFNews ReleaseMorphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
2023-05-11 08:00U:MORFNews ReleaseMorphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
2023-05-05 10:31U:MORFNews ReleaseMorphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters ¢ € ™ Option to Purchase Additional Shares
2023-05-03 00:13U:MORFNews ReleaseMorphic Therapeutic Announces Pricing of $240.0 Million Public Offering
2023-05-02 16:02U:MORFNews ReleaseMorphic Therapeutic Announces Proposed Public Offering
2023-04-25 07:00U:MORFNews ReleaseMorphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
2023-04-25 06:59U:MORFNews ReleaseMorphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
2023-04-24 16:01U:MORFNews ReleaseMorphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023